{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:28:47Z","timestamp":1793921327995,"version":"4.8.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2023-ct06"],"award-info":[{"award-number":["lzujbky-2023-ct06"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gansu Province Major Science and Technology Special Project","award":["24ZDFA007"],"award-info":[{"award-number":["24ZDFA007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07275-8","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:56:37Z","timestamp":1762253797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["JUN\u2013ENPP1\u2013cGAS\u2013STING axis mediates immune evasion and tumor progression in bladder cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Chengyu","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8862-4445","authenticated-orcid":false,"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"7275_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7275_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.","journal-title":"Nat Rev Dis Primers"},{"key":"7275_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Epidemiology, Screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5:628\u201339.","journal-title":"Eur Urol Oncol"},{"key":"7275_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital Organs-Part B: prostate and bladder tumours. Eur Urol. 2016;70:106\u201319.","journal-title":"Eur Urol"},{"key":"7275_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57:766\u201373.","journal-title":"Eur Urol"},{"key":"7275_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","volume":"69","author":"PL Crispen","year":"2020","unstructured":"Crispen PL, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020;69:3\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"7275_CR7","doi-asserted-by":"publisher","first-page":"1537808","DOI":"10.3389\/fimmu.2025.1537808","volume":"16","author":"P Huang","year":"2025","unstructured":"Huang P, Wang J, Yu Z, Lu J, Sun Z, Chen Z. Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion. Front Immunol. 2025;16:1537808.","journal-title":"Front Immunol"},{"key":"7275_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carrion A, Cathomas R, Comperat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85:17\u201331.","journal-title":"Eur Urol"},{"key":"7275_CR9","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, et al. Adjuvant nivolumab versus placebo in Muscle-Invasive urothelial carcinoma. N Engl J Med. 2021;384:2102\u201314.","journal-title":"N Engl J Med"},{"key":"7275_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"7275_CR11","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullen A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J, et al. Avelumab First-Line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after >\/=2 years of Follow-Up. J Clin Oncol. 2023;41:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"7275_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, et al. Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"key":"7275_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-Sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"7275_CR14","doi-asserted-by":"publisher","first-page":"216409","DOI":"10.1016\/j.canlet.2023.216409","volume":"577","author":"Z Liu","year":"2023","unstructured":"Liu Z, Wang D, Zhang J, Xiang P, Zeng Z, Xiong W, Shi L. cGAS-STING signaling in the tumor microenvironment. Cancer Lett. 2023;577:216409.","journal-title":"Cancer Lett"},{"key":"7275_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, van der Velden AWM, Martinez LA. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494\u2013e508495.","journal-title":"Cancer Cell"},{"key":"7275_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12032-024-02539-7","volume":"41","author":"S Islam","year":"2024","unstructured":"Islam S, Islam MM, Akhand MRN, Park BY, Akanda MR. Recent advancements in cGAS-STING activation, tumor immune evasion, and therapeutic implications. Med Oncol. 2024;41:291.","journal-title":"Med Oncol"},{"key":"7275_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00441-002-0651-7","volume":"310","author":"B Grobben","year":"2002","unstructured":"Grobben B, De Deyn PP, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;310:257\u201370.","journal-title":"Cell Tissue Res"},{"key":"7275_CR18","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1038\/s41467-018-06922-7","volume":"9","author":"K Kato","year":"2018","unstructured":"Kato K, Nishimasu H, Oikawa D, Hirano S, Hirano H, Kasuya G, Ishitani R, Tokunaga F, Nureki O. Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1. Nat Commun. 2018;9:4424.","journal-title":"Nat Commun"},{"key":"7275_CR19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nchembio.1661","volume":"10","author":"L Li","year":"2014","unstructured":"Li L, Yin Q, Kuss P, Maliga Z, Millan JL, Wu H, Mitchison TJ. Hydrolysis of 2\u20193\u2019-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10:1043\u20138.","journal-title":"Nat Chem Biol"},{"key":"7275_CR20","doi-asserted-by":"crossref","unstructured":"Onyedibe KI, Wang M, Sintim HO. ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1. Molecules 2019;24.","DOI":"10.3390\/molecules24224192"},{"key":"7275_CR21","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727\u201342.","journal-title":"Am J Cancer Res"},{"key":"7275_CR22","doi-asserted-by":"crossref","unstructured":"Lee HJ, Oh JY. Mesenchymal Stem\/Stromal cells induce Myeloid-Derived Suppressor Cells in the Bone Marrow via the Activation of the c-Jun N-Terminal Kinase Signaling Pathway. Int J Mol Sci. 2024;25.","DOI":"10.20944\/preprints202401.0708.v1"},{"key":"7275_CR23","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z Ni","year":"2022","unstructured":"Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L, et al. JNK signaling promotes bladder cancer immune escape by regulating METTL3-Mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82:1789\u2013802.","journal-title":"Cancer Res"},{"key":"7275_CR24","doi-asserted-by":"publisher","first-page":"e2308131","DOI":"10.1002\/advs.202308131","volume":"11","author":"Y An","year":"2024","unstructured":"An Y, Zhu J, Xie Q, Feng J, Gong Y, Fan Q, Cao J, Huang Z, Shi W, Lin Q, et al. Tumor Exosomal ENPP1 hydrolyzes cGAMP to inhibit cGAS-STING signaling. Adv Sci (Weinh). 2024;11:e2308131.","journal-title":"Adv Sci (Weinh)"},{"key":"7275_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","volume":"559","author":"SM Haag","year":"2018","unstructured":"Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R, Ablasser A. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559:269\u201373.","journal-title":"Nature"},{"key":"7275_CR26","doi-asserted-by":"publisher","first-page":"16020","DOI":"10.1021\/acs.jmedchem.1c01409","volume":"64","author":"P Russomanno","year":"2021","unstructured":"Russomanno P, Assoni G, Amato J, D\u2019Amore VM, Scaglia R, Brancaccio D, Pedrini M, Polcaro G, La Pietra V, Orlando P, et al. Interfering with the Tumor-Immune interface: making way for Triazine-Based small molecules as novel PD-L1 inhibitors. J Med Chem. 2021;64:16020\u201345.","journal-title":"J Med Chem"},{"key":"7275_CR27","doi-asserted-by":"crossref","unstructured":"Wang J. TFTF: an R-Based Integrative Tool for Decoding Human Transcription Factor-Target Interactions. Biomolecules 2024;14.","DOI":"10.3390\/biom14070749"},{"key":"7275_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/cdd.2014.12","volume":"21","author":"J Bageritz","year":"2014","unstructured":"Bageritz J, Puccio L, Piro RM, Hovestadt V, Phillips E, Pankert T, Lohr J, Herold-Mende C, Lichter P, Goidts V. Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell Death Differ. 2014;21:929\u201340.","journal-title":"Cell Death Differ"},{"key":"7275_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","volume":"11","author":"J Li","year":"2021","unstructured":"Li J, Duran MA, Dhanota N, Chatila WK, Bettigole SE, Kwon J, Sriram RK, Humphries MP, Salto-Tellez M, James JA, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 2021;11:1212\u201327.","journal-title":"Cancer Discov"},{"key":"7275_CR30","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3892\/ijo.2014.2648","volume":"45","author":"RG Manzano","year":"2014","unstructured":"Manzano RG, Martinez-Navarro EM, Forteza J, Brugarolas A. Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in Estrogen receptor-negative breast cancers. Int J Oncol. 2014;45:2250\u201366.","journal-title":"Int J Oncol"},{"key":"7275_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BJ20040465","volume":"381","author":"A Cimpean","year":"2004","unstructured":"Cimpean A, Stefan C, Gijsbers R, Stalmans W, Bollen M. Substrate-specifying determinants of the nucleotide pyrophosphatases\/phosphodiesterases NPP1 and NPP2. Biochem J. 2004;381:71\u20137.","journal-title":"Biochem J"},{"key":"7275_CR32","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"S Vigano","year":"2019","unstructured":"Vigano S, Alatzoglou D, Irving M, Menetrier-Caux C, Caux C, Romero P, Coukos G. Targeting adenosine in cancer immunotherapy to enhance T-Cell function. Front Immunol. 2019;10:925.","journal-title":"Front Immunol"},{"key":"7275_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:765.","journal-title":"Nat Rev Cancer"},{"key":"7275_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves Anti-tumor immune responses. Cancer Cell. 2016;30:391\u2013403.","journal-title":"Cancer Cell"},{"key":"7275_CR35","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.4049\/jimmunol.0901247","volume":"183","author":"A Ohta","year":"2009","unstructured":"Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M. A2A adenosine receptor May allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009;183:5487\u201393.","journal-title":"J Immunol"},{"key":"7275_CR36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK. Adenosine receptor 2A Blockade increases the efficacy of Anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3:506\u201317.","journal-title":"Cancer Immunol Res"},{"key":"7275_CR37","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated Inhibition. Science. 2017;355:1428\u201333.","journal-title":"Science"},{"key":"7275_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367.","journal-title":"Nat Rev Immunol"},{"key":"7275_CR39","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al. Tumor interferon signaling regulates a Multigenic resistance program to immune checkpoint Blockade. Cell. 2016;167:1540\u2013e15541512.","journal-title":"Cell"},{"key":"7275_CR40","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"7275_CR41","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"7275_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","volume":"22","author":"J Amersfoort","year":"2022","unstructured":"Amersfoort J, Eelen G, Carmeliet P. Immunomodulation by endothelial cells - partnering up with the immune system? Nat Rev Immunol. 2022;22:576\u201388.","journal-title":"Nat Rev Immunol"},{"key":"7275_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","volume":"108","author":"TM Bui","year":"2020","unstructured":"Bui TM, Wiesolek HL, Sumagin R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020;108:787\u201399.","journal-title":"J Leukoc Biol"},{"key":"7275_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380.","journal-title":"Science"},{"key":"7275_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859\u201374.","journal-title":"Immunity"},{"key":"7275_CR46","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S. Adenosine-A2A receptor pathway in cancer immunotherapy. Front Immunol. 2022;13:837230.","journal-title":"Front Immunol"},{"key":"7275_CR47","doi-asserted-by":"crossref","unstructured":"Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. Int J Mol Sci 2020, 21.","DOI":"10.3390\/ijms21207619"},{"key":"7275_CR48","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, Feng L, Sher T, DuPage M. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity. 2023;56:1613\u2013e16301615.","journal-title":"Immunity"},{"key":"7275_CR49","doi-asserted-by":"crossref","unstructured":"Aldinucci D, Borghese C, Casagrande N. The CCL5\/CCR5 Axis in Cancer Progression. Cancers (Basel) 2020, 12.","DOI":"10.3390\/cancers12071765"},{"key":"7275_CR50","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin N. CXCR3 ligands in cancer and Autoimmunity, chemoattraction of effector T Cells, and beyond. Front Immunol. 2020;11:976.","journal-title":"Front Immunol"},{"key":"7275_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29:10\u201321.","journal-title":"Cancer Gene Ther"},{"key":"7275_CR52","doi-asserted-by":"crossref","unstructured":"Mowat C, Mosley SR, Namdar A, Schiller D, Baker K. Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. J Exp Med 2021, 218.","DOI":"10.1084\/jem.20210108"},{"key":"7275_CR53","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41419-020-2546-5","volume":"11","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Jia S, Shao C, Shi Y. Irradiation induces cancer lung metastasis through activation of the cGAS-STING-CCL5 pathway in mesenchymal stromal cells. Cell Death Dis. 2020;11:326.","journal-title":"Cell Death Dis"},{"key":"7275_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18:152.","journal-title":"Mol Cancer"},{"key":"7275_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"7275_CR56","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S. Reis e Sousa C: NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172:1022\u2013e10371014.","journal-title":"Cell"},{"key":"7275_CR57","doi-asserted-by":"publisher","first-page":"1022136","DOI":"10.3389\/fimmu.2022.1022136","volume":"13","author":"N Mabrouk","year":"2022","unstructured":"Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E, Tartour E. CXCR6 expressing T cells: functions and role in the control of tumors. Front Immunol. 2022;13:1022136.","journal-title":"Front Immunol"},{"key":"7275_CR58","doi-asserted-by":"crossref","unstructured":"Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P et al. CX3CR1 identifies PD-1 therapy-responsive CD8\u2009+\u2009T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 2018, 3.","DOI":"10.1172\/jci.insight.97828"},{"key":"7275_CR59","doi-asserted-by":"publisher","first-page":"114289","DOI":"10.1016\/j.celrep.2024.114289","volume":"43","author":"PK Purbey","year":"2024","unstructured":"Purbey PK, Seo J, Paul MK, Iwamoto KS, Daly AE, Feng AC, Champhekar AS, Langerman J, Campbell KM, Schaue D, et al. Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. Cell Rep. 2024;43:114289.","journal-title":"Cell Rep"},{"key":"7275_CR60","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massague J. Transforming growth Factor-beta signaling in immunity and cancer. Immunity. 2019;50:924\u201340.","journal-title":"Immunity"},{"key":"7275_CR61","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, et al. TGFbeta attenuates tumour response to PD-L1 Blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"7275_CR62","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Canellas A, Hernando-Momblona X, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343.","journal-title":"Nature"},{"key":"7275_CR63","doi-asserted-by":"publisher","first-page":"106938","DOI":"10.1016\/j.imlet.2024.106938","volume":"270","author":"J Busselaar","year":"2024","unstructured":"Busselaar J, Sijbranda M, Borst J. The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer. Immunol Lett. 2024;270:106938.","journal-title":"Immunol Lett"},{"key":"7275_CR64","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","volume":"36","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36:250\u20136.","journal-title":"Trends Immunol"},{"key":"7275_CR65","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.humimm.2020.12.005","volume":"82","author":"A Churov","year":"2021","unstructured":"Churov A, Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy. Hum Immunol. 2021;82:270\u20138.","journal-title":"Hum Immunol"},{"key":"7275_CR66","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","volume":"24","author":"MT Anvar","year":"2024","unstructured":"Anvar MT, Rashidan K, Arsam N, Rasouli-Saravani A, Yadegari H, Ahmadi A, Asgari Z, Vanan AG, Ghorbaninezhad F, Tahmasebi S. Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies? Cancer Cell Int. 2024;24:355.","journal-title":"Cancer Cell Int"},{"key":"7275_CR67","doi-asserted-by":"crossref","unstructured":"Greten TF, Zhao F, Gamrekelashvili J, Korangy F. Human Th17 cells in patients with cancer: Friends or Foe? Oncoimmunology. 2012;1:1438\u20139.","DOI":"10.4161\/onci.21245"},{"key":"7275_CR68","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1172\/JCI33342","volume":"118","author":"B Guo","year":"2008","unstructured":"Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest. 2008;118:1680\u201390.","journal-title":"J Clin Invest"},{"key":"7275_CR69","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cellimm.2018.09.004","volume":"339","author":"X Li","year":"2019","unstructured":"Li X, Liang D, Shao H, Born WK, Kaplan HJ, Sun D. Adenosine receptor activation in the Th17 autoimmune responses of experimental autoimmune uveitis. Cell Immunol. 2019;339:24\u20138.","journal-title":"Cell Immunol"},{"key":"7275_CR70","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.4049\/jimmunol.1100117","volume":"186","author":"JM Wilson","year":"2011","unstructured":"Wilson JM, Kurtz CC, Black SG, Ross WG, Alam MS, Linden J, Ernst PB. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. J Immunol. 2011;186:6746\u201352.","journal-title":"J Immunol"},{"key":"7275_CR71","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s12010-024-05073-4","volume":"197","author":"X Yang","year":"2025","unstructured":"Yang X, Qi Y, Wang S. DKN-01 suppresses gastric cancer progression through activating cGAS-STING pathway to block macrophage M2 polarization. Appl Biochem Biotechnol. 2025;197:1025\u201338.","journal-title":"Appl Biochem Biotechnol"},{"key":"7275_CR72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40364-025-00750-w","volume":"13","author":"W Zhang","year":"2025","unstructured":"Zhang W, Huang X. Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy. Biomark Res. 2025;13:43.","journal-title":"Biomark Res"},{"key":"7275_CR73","doi-asserted-by":"publisher","first-page":"10466","DOI":"10.1038\/s41598-022-14297-5","volume":"12","author":"A Kabashima","year":"2022","unstructured":"Kabashima A, Matsuo Y, Ito S, Akiyama Y, Ishii T, Shimada S, Masamune A, Tanabe M, Tanaka S. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer. Sci Rep. 2022;12:10466.","journal-title":"Sci Rep"},{"key":"7275_CR74","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cellsig.2009.12.008","volume":"22","author":"E Shaulian","year":"2010","unstructured":"Shaulian E. AP-1\u2013The Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal. 2010;22:894\u20139.","journal-title":"Cell Signal"},{"key":"7275_CR75","doi-asserted-by":"crossref","unstructured":"Jafri Z, Li Y, Zhang J, O\u2019Meara CH, Khachigian LM. Jun, an Oncological Foe or Friend? Int J Mol Sci 2025;26.","DOI":"10.3390\/ijms26020555"},{"key":"7275_CR76","doi-asserted-by":"publisher","first-page":"107731","DOI":"10.1016\/j.celrep.2020.107731","volume":"31","author":"K Berthenet","year":"2020","unstructured":"Berthenet K, Castillo Ferrer C, Fanfone D, Popgeorgiev N, Neves D, Bertolino P, Gibert B, Hernandez-Vargas H, Ichim G. Failed apoptosis enhances melanoma cancer cell aggressiveness. Cell Rep. 2020;31:107731.","journal-title":"Cell Rep"},{"key":"7275_CR77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13073-018-0597-3","volume":"10","author":"M Tanioka","year":"2018","unstructured":"Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med. 2018;10:86.","journal-title":"Genome Med"},{"key":"7275_CR78","doi-asserted-by":"publisher","first-page":"e14550","DOI":"10.1200\/JCO.2022.40.16_suppl.e14550","volume":"40","author":"I Csiki","year":"2022","unstructured":"Csiki I, Dong A, Tuan BY, John E, O\u2019Toole L, Seppa J, Huang N, Hawley RC, Exon C, Glenn JS. First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer. J Clin Oncol. 2022;40:e14550\u201314550.","journal-title":"J Clin Oncol"},{"key":"7275_CR79","doi-asserted-by":"publisher","first-page":"105549","DOI":"10.1016\/j.bioorg.2021.105549","volume":"119","author":"M Gangar","year":"2022","unstructured":"Gangar M, Goyal S, Raykar D, Khurana P, Martis AM, Goswami A, Ghoshal I, Patel KV, Nagare Y, Raikar S, et al. Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy. Bioorg Chem. 2022;119:105549\u2013105549.","journal-title":"Bioorg Chem"},{"key":"7275_CR80","doi-asserted-by":"publisher","first-page":"116006","DOI":"10.1016\/j.bcp.2023.116006","volume":"220","author":"R Huang","year":"2024","unstructured":"Huang R, Ning Q, Zhao J, Zhao X, Zeng L, Yi Y, Tang S. Targeting ENPP1 for cancer immunotherapy: killing two birds with one stone. Biochem Pharmacol. 2024;220:116006.","journal-title":"Biochem Pharmacol"},{"key":"7275_CR81","doi-asserted-by":"crossref","unstructured":"Johnson RM, Wang S, Carozza JA, Fernandez D, Scicinski J, Verity NA, Mardjuki R, Cao X, Papkoff J, Ray N, Li L. ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy. bioRxiv 2025.","DOI":"10.1101\/2025.05.18.654655"},{"key":"7275_CR82","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1038\/s41467-025-59874-0","volume":"16","author":"C Pu","year":"2025","unstructured":"Pu C, Cui H, Yu H, Cheng X, Zhang M, Qin L, Ning Z, Zhang W, Chen S, Qian Y, et al. Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. Nat Commun. 2025;16:4793.","journal-title":"Nat Commun"},{"key":"7275_CR83","unstructured":"First-In-Human A. Phase 1 a\/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. 2022."},{"key":"7275_CR84","unstructured":"Phase D 1, Escalation. Safety, tolerability, and pharmacokinetic study of SR-8541A (ENPP1 Inhibitor) administered orally as monotherapy or in combination with checkpoint inhibitors in subjects with advanced\/metastatic solid tumors. 2023."},{"key":"7275_CR85","unstructured":"First-in-human. Phase 1a\/b, Open-Label, Multicenter, dose Escalation, optimization and expansion study of ISM5939 in patients with advanced and\/or metastatic solid tumors. 2024."},{"key":"7275_CR86","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/2159-8290.CD-21-0932","volume":"12","author":"B Ruiz-Fernandez de Cordoba","year":"2022","unstructured":"Ruiz-Fernandez de Cordoba B, Moreno H, Valencia K, Perurena N, Ruedas P, Walle T, Pezonaga-Torres A, Hinojosa J, Guruceaga E, Pineda-Lucena A, et al. Tumor ENPP1 (CD203a)\/Haptoglobin axis exploits Myeloid-Derived suppressor cells to promote Post-Radiotherapy local recurrence in breast cancer. Cancer Discov. 2022;12:1356\u201377.","journal-title":"Cancer Discov"},{"key":"7275_CR87","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1158\/1078-0432.CCR-22-1681","volume":"29","author":"B de Ruiz-Fernandez","year":"2023","unstructured":"de Ruiz-Fernandez B, Martinez-Monge R, Lecanda F. ENPP1 immunobiology as a therapeutic target. Clin Cancer Res. 2023;29:2184\u201393.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07275-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:28:23Z","timestamp":1762295303000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07275-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7275"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07275-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Hospital of Lanzhou University for both human and animal experiments. Human tissue collection and related experiments were approved under Approval No. 2024\u00a0A\u2013948, with written informed consent obtained from all patients prior to tissue collection. Animal experiments were conducted following institutional guidelines and were approved under Approval No. D2024\u2013686.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients involved in this study provided written informed consent for the use of their clinical data for research and publication purposes. The consent process included disclosure that their de\u2013identified data may be made publicly available online and in print following publication. No identifying information (such as name, initials, date of birth, or hospital number) has been included in this manuscript. The study protocol and consent procedures were reviewed and approved by the institutional ethics committee, and all efforts were made to ensure patient confidentiality and compliance with data protection regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial or non\u2013financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1222"}}